Amy Lemay, APRN
Family · Emporia, KSNPI 1780988063
Payments from drug & device makers
Across 132 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$428
- Novo Nordisk$224
- AstraZeneca$204
- Lilly USA, LLC$171
- Phathom Pharmaceuticals, Inc.$160
- Bayer$138
- plus $716 from 19 others
What the payments were for
- Food & beverage$2,033100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $428 |
| Novo Nordisk | 14 | $224 |
| AstraZeneca | 10 | $204 |
| Lilly USA, LLC | 11 | $171 |
| Phathom Pharmaceuticals, Inc. | 8 | $160 |
| Bayer | 8 | $138 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $108 |
| Teva Pharmaceuticals USA, Inc. | 5 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Mylan Specialty L.p. | 2 | $46 |
| Exact Sciences | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $34 |
| Boehringer Ingelheim | 2 | $34 |
| Exeltis, USA Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Amgen | 1 | $16 |
| GSK | 1 | $16 |
| Viatris Specialty LLC | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Abbott | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
How this compares
$2,041 in reported general payments places this provider in the 85th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 18 | $400 |
| Gabapentin | 14 | $324 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $261 |
| Diclofenac Sodium | 11 | $158 |
| Losartan Potassium | 14 | $150 |
| Terbinafine Hcl | 12 | $119 |
| Furosemide | 12 | $110 |
| Hydrochlorothiazide | 22 | $79 |
| Amlodipine Besylate | 35 | $47 |
| Lisinopril | 12 | $16 |
| Levothyroxine Sodium | 13 | $14 |
Paid to pharmacies, not to this prescriber.
Other family in Emporia
- Hannah SchmidtEmporia$6K
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.